2,000-year-old steel acupuncture needles unearthed in China's Jiangxi province
Steel acupuncture needles inside a jade tube discovered in the famed tomb of the Marquis of Haihun in Nanchang, Jiangxi province. - China Daily/ANN
"At least five needle-like objects were visible in the tube's cross-section," said Yang Jun, leader of the excavation team at the Marquis of Haihun's tomb in Jiangxi.
The delicate needles date back over 2,000 years. They were discovered in a jade tube inside a gold-foiled lacquer box and were crafted with steelworking techniques far ahead of their time. Centuries underground have left them corroded and broken, requiring careful analysis to confirm their purpose.
Steel needles and a jade tube discovered in the famed tomb of the Marquis of Haihun. - China Daily/ANN
Each needle measures 0.3 to 0.5mm in diameter. Yang noted that they were likely wrapped in cloth prior to being placed in the jade tube, a practice that ensured hygiene and safe handling.
Gu Man, an expert from the China Academy of Chinese Medical Sciences, said the needles are believed to be the earliest steel medical acupuncture needles discovered in China to date, serving as crucial evidence for the history of steel metallurgy and ancient Chinese medicine during the Western Han Dynasty (206 BC-AD 24). - China Daily/ANN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
Malaysian trucker donates rare Rh-negative blood for 33 years
TANJONG MALIM: A lorry driver's accident 34 years ago led him to a lifelong mission of donating his rare Rh-negative blood, a type difficult to find in Malaysia. S. Shanmugam, 54, has since given blood 54 times, becoming the largest donor of this rare blood type to Raja Permaisuri Bainun Hospital (HRPB). Shanmugam discovered his blood type's rarity after a 1991 accident delayed his surgery due to a lack of matching donors. 'From there, I realised I needed to become a donor out of responsibility,' he said after receiving an award at Slim River Hospital during Perak's World Blood Donor Day celebration. Living in Teluk Intan, Shanmugam donates four times yearly, as Rh-negative blood makes up less than 10% of Malaysia's blood supply. State Health Committee chairman A. Sivanesan presented awards to top donors, including legal consultant Beh Zeng Kang, 29, who has donated 51 times since age 17. Beh, with the common O blood type, said donating is a routine. 'As long as I'm healthy, I'll keep helping those in need,' he said. Sivanesan noted Perak collected 64,416 blood bags last year, with Chinese donors leading at 48.32%, followed by Malays (39.12%) and Indians (11.40%). The state estimates needing 80,000 blood bags annually. Special certificates were given to 36 donors and 15 campaign organisers for their contributions.
The Star
4 hours ago
- The Star
Thai Public Health Minister says cannabis reclassification must avoid backlash; kratom already regulated
BANGKOK: Public Health Minister Somsak Thepsuthin said on Friday (July 4) that the government has not yet set a timeframe for reclassifying cannabis as a narcotic, emphasising the need for a balanced approach to avoid disrupting the cannabis industry and public backlash. Speaking to reporters, Somsak acknowledged that since cannabis was decriminalised in 2022, over 18,000 dispensaries have opened nationwide, with total investment reaching 30–40 billion baht. Any move to reclassify it as a narcotic must therefore ensure that it does not harm investors, spark protests, or lead to lawsuits. To manage the situation, the ministry has declared cannabis a controlled herbal substance, meaning it can only be used with a prescription. Somsak explained that only two professions currently authorised to issue prescriptions are modern medical doctors and traditional Thai medicine practitioners, both regulated by their respective professional councils. Other healthcare professions, even if previously permitted, do not yet have the regulatory authority to prescribe cannabis until formal guidelines are introduced. Training and public education will be required to support this system. "Declaring cannabis a narcotic immediately would impact 18,000 businesses," said Somsak. "We must act carefully. The government doesn't want the public to suffer. Today, people are already complaining about cannabis smoke. So, regulation is essential." On the topic of kratom, Somsak confirmed that it is already regulated under a dedicated law. Only fresh leaves may be sold, and kratom tea may be brewed and consumed at home, but commercial sale of processed forms is prohibited. Nonetheless, the minister noted the potential for medicinal value. According to the Department of Medical Sciences, just over one tonne of kratom can be used to extract one litre of mitragynine, which currently fetches over 1 million baht per litre on the market. The government, he said, is open to allowing beneficial uses of the plant under proper control. - The Nation/ANN
Malaysian Reserve
a day ago
- Malaysian Reserve
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ — Brii Biosciences Limited ('Brii Bio,' stock code: a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ('Joincare Group'). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: 'The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections.' Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, 'The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options.' About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ('Brii Bio', stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
